Project Grant R01CA300807
Award Date 8/5/26
Completion Date 7/31/31
Dollars Obligated $529K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Cancer Institute awarded the University of Virginia $484,387 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel statistical methods for the design, analysis, and implementation of enzyme-linked immunospot (ELISPOT) experiments. The project addresses inconsistency in how ELISPOT assay data—used to quantify cytokine-secreting cells in basic, clinical, and translational immunotherapy studies—are analyzed across research settings. Current practice...
- The National Cancer Institute awarded the University of Virginia $404,349 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on April 1, 2026, to develop and validate quantitative magnetic resonance imaging methods for measuring macromolecular delivery to brain tumors following focused ultrasound and microbubble treatment. The research addresses the blood-tumor barrier, which limits therapeutic drug delivery to brain metastases and contributes to higher patient mortality...
- The National Cancer Institute awarded the University of Virginia $514,563 under the Cancer Treatment Research program (CFDA 93.395) on September 1, 2026, to develop adaptive randomization designs for identifying optimal dose combinations in early-phase clinical trials applicable to both oncology and non-oncology agents. The project targets the practical implementation of FDA Project Optimus principles by creating flexible early-stage trial designs that balance treating study participants with...
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...
- The National Institutes of Health National Cancer Institute awarded the University of Virginia $730,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify N6-methyladenosine (M6A) marks and genes influencing lung cancer risk. The award funds a five-year project (August 1, 2026 through July 31, 2031) combining genetic epidemiology, multi-omics analysis, and in vitro studies to characterize M6A's role in lung tumorigenesis. The work includes conducting an...
- The National Cancer Institute awarded the University of Miami $614,453 on August 24, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing Number) to develop anti-ST2 theranostic nanobodies for colorectal cancer immunotherapy. The award funds development and characterization of murine and human single-domain antibodies (nanobodies) targeting ST2 (interleukin-33 receptor), a novel immune checkpoint target for advanced colorectal cancer. Work includes generating...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of California Irvine $648,626 on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy. The funded research examines why PD-1 checkpoint inhibitors fail in most cancer patients despite providing durable benefits in approximately 40 percent of patients with metastatic melanoma and...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...